A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma

Cancer

Volumn 78, Issue 10, 1996, Pages 2070-2077

  Spiridonidis, C Harris ^a   Laufman, Leslie R ^a   Jones, Jacqueline J ^a   Gray, D Jeffrey ^b   Cho, Chuck C ^b   Young, Donn C ^c  

^a Hematology/Oncology Consultants Inc   (United States)

^b GRANT MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

chemotherapy; dysphagia relief; esophageal adenocarcinoma; etoposide; high dose cisplatin

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DYSPHAGIA; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; TINNITUS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; SURVIVAL RATE;

EID: 0029956749     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2070::AID-CNCR6>3.0.CO;2-S     Document Type: Article

References (30)

1. Hesketh PJ, Clapp RW, Doos WG, Spechler J. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989;64:526-30.
2. Blot WJ, Devessa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
3. Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Anticancer Drugs 1993;4:287-99.
4. Ajani JA, Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 1994;21:474-82.
5. Nanus DM, Kelsen DP, Niedzwiecki D, Chapman D, Brennan M, Cheng E, et al. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Oncol 1989;7:1105-12.
6. Sickle-Santanello BJ, Farrar WB, DeCenzo JF, Sedigheh KR, Klein J, Pearl D, et al. Technical and statistical improvements for flow cytometric DNA analysis of paraffin-embedded tissue. Cytometry 1988;9:594-9.
7. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. American Joint Committee on Cancer manual for staging of cancer. 4th ed. Philadelphia: JB Lippincott, 1992:57-71.
8. Spiridonidis CH, Laufman LR, Stydnicki KA, Noltimier JW, Cho CC, Young DC, et al. Decline of tumor markers following therapy of non-small-cell lung cancer: a useful outcome predictor. Cancer 1995;75:1586-93.
9. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91.
10. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990;8:1231-8.
11. Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 1992;10:1037-42.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations, J Am Stat Assoc 1958;53:457-81.
13. Hryniuk WM, Goodyear M. The calculation of received dose intensity [editorial]. J Clin Oncol 1990;8:1935-7.
14. Simon RS. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986;105:429-35.
15. Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer 1995;76:1120-5.
16. Ajani JA, Roth JA, Ryan B, Putnam JB, Pazdur R, Levin B, et al. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1993; 11: 22-8.
17. Kelsen D, Lovett D, Wong J, Saltz L, Buckley M, Murray P, et al. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 1992;10:269-74.
18. Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Kereztes R, et al. A phase II trial of interferon alpha-2a, 5-fluorouracil and cisplatin in patients with advanced esophageal adenocarcinoma. Cancer 1995;75:2197-202.
19. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 1995;22:35-40.
20. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors, Semin Oncol 1995;22:46-50.
21. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993;11:873-8.
22. Rothenberg MC, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC. Dose-intensive induction therapy with cyclophosphamide, cisplatin and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 1992;10:727-34.
23. Adelstein DJ, Rice TW, Boyce GA, Sivak MV, Van Kirk MA, Kirby TJ, et al. Adenocarcinoma of the esophagus and gastroesophageal junction: clinical and pathologic assessment of response to induction chemotherapy. Am J Clin Oncol 1994;17:14-8.
24. Nichols CR, Williams SD, Loehrer PJ, Greco AP, Crawford DE, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
25. Kelsen DP, Heelan R, Coonley C, Bains M, Martini N, Hilaris B, et al. Clinical and pathological evaluation of response to chemotherapy in patients with esophageal carcinoma. Am J Clin Oncol 1983;6:539-41.
26. Caspers RJ, Welvaart K, Verkes RJ, Hermans J, Leer JW. The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. Radiother Oncol 1988;12:15-23.
27. Coia LR, Soffen EM, Schultheiss TE, Martin EE, Hanks GE. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 1993;71:281-6.
28. Herscovic A, Martz L, Al Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy combined with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
29. Coia L, Engstrom P, Paul A, Stafford P, Hanks G. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma, Int J Radiat Oncol Biol Phys 1991;20:29-36.
30. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II Intergroup trial 0122. J Clin Oncol 1996;14:149-55.